APLM
BEARISH
$19.9
Live
Apollomics, Inc. · NASDAQ
$3.66
52W Range
$42.12
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$42.65M
P/E
N/A
ROE
-380.1%
Profit margin
N/A
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
APLM's Piotroski F-Score of 3/9 indicates weak financial health, with significant red flags in profitability, cash flow, and leverage. The company exhibits extreme negative profitability metrics, including a -124.8% operating margin and -380.13% ROE, despite a 380.8% YoY revenue growth. With no Altman Z-Score available and a current ratio of 0.97, liquidity concerns persist. The stock trades at a high Price/Sales of 6.15 and a negative forward P/E of -30.62, suggesting valuation is driven by speculative growth expectations rather than fundamentals. The 52-week price range of $3.66 to $42.12 reflects extreme volatility, and the 5-year return of -98.0% underscores long-term underperformance.
Key Strengths
380.8% YoY revenue growth indicates strong top-line expansion
100.0% gross margin suggests efficient cost structure on sales
Recent 6-month return of +191.4% shows strong short-term momentum
Low market cap ($0.04B) offers potential for high volatility-driven upside
Insider sentiment at 40/100 suggests cautious but not outright negative insider positioning
Key Risks
Piotroski F-Score of 3/9 signals severe financial distress and weak operational health
Negative ROE (-380.13%) and ROA (-72.29%) indicate deep losses relative to equity and assets
Operating margin of -124.8% reflects unsustainable cost structure or one-time expenses
No available debt/equity or cash/debt data raises transparency and solvency concerns
No analyst coverage or target price indicates lack of institutional interest and high uncertainty
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
24
Weak
25
55
20
18
0
AI Verdict
Weak
Key drivers: Low Piotroski F-Score (3/9), Negative profitability and ROE, High valuation multiples without earnings support, Lack of analyst coverage, Extreme price volatility
Confidence
88%
Value
25/100
Ref P/E, PEG, Graham Number
Positives
- High revenue growth (380.8% YoY) may justify premium valuation
- Price/Sales of 6.15 is below sector average (164.76) in context of negative sector P/E
Watchpoints
- No Graham Number or intrinsic value due to lack of earnings
- Negative forward P/E (-30.62) implies no earnings in near term
- Price/Book of -4.99 indicates negative book value, invalidating traditional valuation
Future
55/100
Ref Growth rates
Positives
- 380.8% YoY revenue growth suggests strong growth potential
- Recent 6-month return of +191.4% indicates market optimism
Watchpoints
- No earnings growth data available
- Negative operating margin (-124.8%) suggests growth is not yet profitable
- No free cash flow or operating cash flow data
Past
20/100
Ref Historical trends
Positives
- 1-year return of +148.8% shows recent recovery from lows
Watchpoints
- 5-year return of -98.0% indicates prolonged underperformance
- 52-week low of $3.66 vs. high of $42.12 shows extreme volatility
- 3-year return of -98.1% reflects persistent decline
Health
18/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- 100.0% gross margin indicates strong product-level profitability
Watchpoints
- Piotroski F-Score of 3/9 indicates weak financial health
- Current ratio of 0.97 and quick ratio of 0.91 suggest borderline liquidity
- No Altman Z-Score available, but negative ROE and operating margin imply distress risk
- Negative ROE and ROA indicate capital is being destroyed
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend yield and payout ratio are N/A
- Dividend strength is 0/100
- No history or expectation of dividends
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$19.9
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for APLM and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
APLM
Apollomics, Inc.
Primary
|
-98.0% | -98.1% | +148.8% | +191.4% | -0.5% | -0.8% |
|
RLYB
Rallybio Corporation
Peer
|
-92.7% | -76.3% | +311.0% | +92.1% | -12.2% | -2.6% |
|
INCR
InterCure Ltd.
Peer
|
-91.7% | -67.4% | -37.5% | -52.3% | -4.7% | +0.4% |
|
ZYBT
Zhengye Biotechnology Holding Limited
Peer
|
-81.1% | -81.1% | -88.2% | -63.5% | +5.8% | -10.7% |
|
ARAY
Accuray Incorporated
Peer
|
-93.2% | -87.0% | -78.7% | -76.4% | -27.4% | -24.4% |
APL
Apollomics, Inc.
Primary
5Y
-98.0%
3Y
-98.1%
1Y
+148.8%
6M
+191.4%
1M
-0.5%
1W
-0.8%
RLY
Rallybio Corporation
Peer
5Y
-92.7%
3Y
-76.3%
1Y
+311.0%
6M
+92.1%
1M
-12.2%
1W
-2.6%
INC
InterCure Ltd.
Peer
5Y
-91.7%
3Y
-67.4%
1Y
-37.5%
6M
-52.3%
1M
-4.7%
1W
+0.4%
ZYB
Zhengye Biotechnology Holding Limited
Peer
5Y
-81.1%
3Y
-81.1%
1Y
-88.2%
6M
-63.5%
1M
+5.8%
1W
-10.7%
ARA
Accuray Incorporated
Peer
5Y
-93.2%
3Y
-87.0%
1Y
-78.7%
6M
-76.4%
1M
-27.4%
1W
-24.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-30.62
PEG Ratio
N/A
P/B Ratio
-4.99
P/S Ratio
6.15
EV/Revenue
2.97
EV/EBITDA
-0.78
Market Cap
$42.65M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-124.8%
Gross Margin
100.0%
ROE
-380.13%
ROA
-72.29%
Growth
Revenue and earnings growth rates
Revenue Growth
+380.8%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
0.97
Weak
Quick Ratio
0.91
Poor
Cash/Share
$1.9
Healthcare Sector Comparison
Comparing APLM against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-380.13%
This Stock
vs
-88.14%
Sector Avg
+331.3%
(Excellent)
Revenue Growth
380.8%
This Stock
vs
124.04%
Sector Avg
+207.0%
(Fast Growth)
Current Ratio
0.97
This Stock
vs
4.47
Sector Avg
-78.4%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
APLM
Apollomics, Inc.
|
BEARISH | $42.65M | - | -380.1% | -% | $19.9 | |
|
RLYB
Rallybio Corporation
|
BEARISH | $43.48M | - | -15.0% | -% | $8.22 | Compare |
|
INCR
InterCure Ltd.
|
BEARISH | $41.72M | - | -16.7% | -29.2% | $0.76 | Compare |
|
ZYBT
Zhengye Biotechnology...
|
BEARISH | $43.6M | - | -6.4% | -12.6% | $0.92 | Compare |
|
ARAY
Accuray Incorporated
|
BEARISH | $44.0M | - | -70.3% | -8.2% | $0.37 | Compare |
APLM
Apollomics, Inc.
BEARISH
Mkt Cap
$43M
P/E
-
ROE
-380.1%
Price
$19.9
Past News Coverage
Recent headlines mentioning APLM from our newsroom.
Newest → oldest
No matching news yet.